Cancer research
Research conducted at the Gansu University of Chinese Medicine in People's Republic of China has led to a potential breakthrough in the treatment of non-small cell lung cancer (NSCLC). The study, published in the journal Frontiers in Oncology, investigates the benefits and risks of combining Fuzheng Yiliu Decoction,
Lymphomas
Researchers at Guangxi Medical University Cancer Hospital have conducted a retrospective study to evaluate the efficacy and safety of zanubrutinib combined with salvage chemotherapy in transplant-ineligible patients with relapsed or refractory (R/R) non-GCB diffuse large B-cell lymphoma (DLBCL). The study found that zanubrutinib combined with either bendamustine and rituximab
Chemotherapy
Researchers at Tongji University School of Medicine in Shanghai, People's Republic of China, have made a significant breakthrough in the treatment of colorectal cancer (CRC) by harnessing the symbiotic relationship between bacteria and CRC. The study, published in the Journal of Controlled Release, reveals that engineered tumor-symbiotic bacterial
Chemotherapy
Research has been ongoing at the University of New Mexico Health Sciences Center to identify effective therapies for ovarian cancer, which remains the deadliest gynecological cancer due to late-stage diagnosis and high rates of chemotherapy resistance and recurrence. To address this challenge, researchers have been exploring the use of patient-derived
Cancer
As Tammie Thrower lay in palliative care, her primary concern was finding a place to live. Despite battling stage four bowel cancer since 2023, she was evicted from her home in January, thrusting her into homelessness. Her story, though shocking, is common in Brisbane, where 21 people died of diagnosed
Cancer
Scientists at University College London have engineered a rare type of immune cell, ðþð³T cells, to survive longer and grow faster, and when supercharged with a B7-H3 antibody, they can use two methods of attack to kill cancer cells. This breakthrough could lead to new treatments for people with
Cancer
Research at Al-Ahliyya Amman University has shed light on the role of kinesin superfamily proteins in cancer, particularly in mediating sensitivity to chemotherapy. The study found that aberrant expression of these proteins contributes to resistance to chemotherapy in various types of cancer, including breast, lung, and prostate cancers. The research
Cancer
Residents of Sverdlovsk Region, Russia are benefiting from the national project Long and Active Life, which has made effective antitumor treatment available to those in need. In one such case, a 60-year-old woman was diagnosed with an early stage malignant neoplasm of the intestine and received timely treatment, leading to
Cancer
Researchers at the National Cancer Center Hospital East in Chiba, Japan, have made significant discoveries regarding the adverse effects of zolbetuximab, a monoclonal antibody used in the treatment of CLDN18.2-positive advanced gastric cancer. The study, published in ESMO Open, highlights the incidence and characteristics of gastritis in patients undergoing
Chemotherapy
Researchers at the First Affiliated Hospital of Jinan University have identified the dual roles of chemotherapy in modulating cytokine dynamics in ovarian cancer, providing valuable insights for addressing resistance and improving combination therapies. The study, published in the International Journal of Cancer, reveals that platinum-based agents and taxanes can trigger
Cancer
Researchers presented new findings from the ACROSS 2 Phase III trial at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC), demonstrating that aumolertinib combined with platinum-pemetrexed chemotherapy significantly improves progression-free survival compared to aumolertinib monotherapy in patients with advanced/metastatic non-small
Cancer
Recent research has shed light on the efficacy and safety of a new treatment regimen for advanced endometrial cancer (aEC). The study, conducted by researchers at Texas Tech University Health Sciences Center, compared the use of lenvatinib combined with pembrolizumab (LVB + PMB) to chemotherapy in patients with aEC. The findings
